01Cingulate reported Q2 2026 earnings per share of -$0.45, beating the consensus estimate of -$0.58 by $0.13 per share, representing a 22% positive surprise.
02The company's stock trades at $4.99 with a market capitalization of $23.4M as of the earnings report date of August 13, 2026.
03Cingulate's earnings performance shows volatility across recent quarters, with a significant miss in Q1 2026 (-79.2% surprise) following the Q2 beat, suggesting inconsistent execution.
04Revenue figures were not disclosed in the earnings report, limiting the ability to assess overall business performance beyond the EPS metric.
Earnings Results
Cingulate (NASDAQ:CING) reported quarterly earnings results on August 13, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.45, beating the consensus estimate of $-0.58 by $0.13 per share. Revenue came in at , meeting the estimate of .
Company Overview
Cingulate's stock moved following the earnings release. The stock currently trades at $4.99 with a market capitalization of $23.4M.
Cingulate's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 22% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Cingulate should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.